Although airway constriction is a hallmark of many diseases, it is often closely associated with asthma and asthma-like conditions. In asthma, obstruction is primarily caused by the narrowing of the airways mediated by the contraction of airway smooth muscle (ASM). Understanding the mechanisms by which ASM contributes to asthma is critical for the development of novel asthma treatments. However, the extent to which ASM shortening results in airway lumen narrowing involves many factors, and thus, deciphering the exact role of ASM in causing asthma symptoms remains a challenging task. To counteract these limitations, ex vivo models have been developed, which provide new insights into the development of new treatments for asthma.
Currently, a variety of models are available to study ASM contraction. Each model has advantages and disadvantages.
Fig.1 Ex Vivo Models. (Creative Biolabs)
Due to the large diameter of the secondary airway, Creative Biolabs has a specific way to test compounds of interest. We provide high-quality ex vivo models and custom solutions to meet your unique needs.
In addition to healthy secondary airways, diseased tissue from donors with asthma is also available. Secondary airway models of disease provide powerful tools for the development of new therapies for asthma.
Due to the small volume of the lower airway, specific systems are required to measure bronchoconstriction or bronchodilation. Our professional team can formulate flexible experimental plans according to your requirements.
At Creative Biolabs, we can also obtain tertiary or lower airway samples from donors with asthma to support your new therapy development.
A variety of ex vivo models allow us to assess the response of bronchodilators to agonism of tertiary or lower airway adrenergic receptors.
Please contact us for more information on ex vivo models as well as customized solutions.